Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and characterization of a standardized adipogenesis assay for testing metabolism disrupting chemicals using human bone marrow derived mesenchymal stem cells.

NAM journal·2026
Same author

GLP-1 Receptor Agonists in Brazil: Landscape of Consumption, Safety and Regulation.

Diabetes, obesity & metabolism·2026
Same author

Heritable changes in chromatin contacts associated with transgenerational susceptibility to diet-induced insulin dysregulation and obesity.

Nature communications·2026
Same author

Correction: de Melo et al. SARS-CoV-2 Spike Protein and Long COVID-Part 2: Understanding the Impact of Spike Protein and Cellular Receptor Interactions on the Pathophysiology of Long COVID Syndrome. <i>Viruses</i> 2025, <i>17</i>, 619.

Viruses·2026
Same author

Thermogenic Differentiation of Human Adipocyte Precursors in Culture: A Systematic Review.

Cells·2025
Same author

A systematic review of exposure to endocrine disruptors and energy expenditure in mice.

Environmental health : a global access science source·2025

Related Experiment Video

Updated: May 20, 2026

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells
07:22

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

Idealized PPARγ-Based Therapies: Lessons from Bench and Bedside.

Angélica Amorim Amato1, Francisco de Assis Rocha Neves

  • 1Laboratório de Farmacologia Molecular, Departamento de Ciências Farmacêuticas, Faculdade de Ciências da Saúde, Universidade de Brasília, Campus Universitário Darcy Ribeiro, Brasília, CEP 70910-900, Brazil.

PPAR Research
|June 30, 2012
PubMed
Summary

Type 2 diabetes (T2D) and insulin resistance are rising, necessitating safer treatments. Research into Peroxisome-proliferator-activated receptor gamma (PPARγ) ligands offers new therapeutic strategies to improve effectiveness and safety.

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

Related Experiment Videos

Last Updated: May 20, 2026

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells
07:22

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Rising incidence of type 2 diabetes (T2D) and insulin resistance globally.
  • Peroxisome-proliferator-activated receptor gamma (PPARγ) is a key regulator of glucose and lipid metabolism.
  • Current T2D drugs targeting PPARγ (TZDs) have efficacy but significant safety concerns.

Purpose of the Study:

  • To review the role of PPARγ in metabolic homeostasis and inflammation.
  • To discuss the limitations and safety concerns associated with existing PPARγ ligands (TZDs).
  • To explore novel strategies for developing safer and more effective PPARγ-based therapies for T2D.

Main Methods:

  • Review of human genetic studies, animal models, and clinical data on PPARγ ligands.
  • Analysis of the mechanisms underlying PPARγ's effects on glucose and lipid homeostasis.
  • Evaluation of safety profiles of current and potential PPARγ modulators.

Main Results:

  • PPARγ plays a crucial role in insulin sensitivity, lipid metabolism, and vascular inflammation.
  • Thiazolidinediones (TZDs) improve hyperglycemia but carry risks like weight gain, bone loss, and cardiovascular toxicity.
  • Recent research provides insights into optimizing PPARγ ligand development for enhanced safety and efficacy.

Conclusions:

  • PPARγ remains a promising therapeutic target for T2D and related metabolic disorders.
  • Overcoming the safety limitations of current PPARγ agonists is critical for future drug development.
  • Optimized ligand design based on new understanding can lead to safer and more effective treatments for insulin resistance.